Abiopharma

🔍 Mikulinsky Oleg (Executive)

Company: CRYO CELL INTERNATIONAL INC (CCEL)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock (Direct)
  Date: 2026-01-07 | Code: H | shares_owned_after: 104,349.00
• Acquired 10,000 shares of Stock Option at $3.54 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2031-01-07 | Exercise: 2026-01-07 | equity_swap_involved: false | shares_owned_after: 10,000.00 | transaction_form_type: 4 | Footnotes: F5
• Acquired 20,000 shares of Stock Option at $3.54 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2031-01-07 | Exercise: 2026-01-07 | equity_swap_involved: false | shares_owned_after: 20,000.00 | transaction_form_type: 4 | Footnotes: F6
• Holds 8,000 shares of Stock Option at $7.49 per share (Derivative)
  Date: 2026-01-07 | Code: H | Expires: 2028-05-21 | Exercise: 2018-05-21 | shares_owned_after: 8,000.00
• Holds 4,444 shares of Stock Option at $7.13 per share (Derivative)
  Date: 2026-01-07 | Code: H | Expires: 2029-09-04 | Exercise: 2019-09-04 | shares_owned_after: 4,444.00
• Holds 1,333 shares of Stock Option at $6.55 per share (Derivative)
  Date: 2026-01-07 | Code: H | Expires: 2030-02-27 | Exercise: 2020-02-27 | shares_owned_after: 1,333.00
• Holds 10,000 shares of Stock Option at $8.0 per share (Derivative)
  Date: 2026-01-07 | Code: H | Expires: 2028-09-23 | Exercise: 2021-09-23 | shares_owned_after: 10,000.00 | Footnotes: F1
• Holds 20,000 shares of Stock Option at $11.9 per share (Derivative)
  Date: 2026-01-07 | Code: H | Expires: 2028-12-28 | Exercise: 2021-12-28 | shares_owned_after: 20,000.00 | Footnotes: F2
• Holds 10,000 shares of Stock Option at $5.88 per share (Derivative)
  Date: 2026-01-07 | Code: H | Expires: 2028-12-22 | Exercise: 2023-12-22 | shares_owned_after: 10,000.00 | Footnotes: F3
• Holds 10,000 shares of Stock Option at $7.35 per share (Derivative)
  Date: 2026-01-07 | Code: H | Expires: 2030-01-21 | Exercise: 2025-01-21 | shares_owned_after: 10,000.00 | Footnotes: F4

Footnotes:

• F1: Stock options vest 1/5 per year commencing on September 23, 2021.
• F2: Stock options vest immediately if the price of the Company's stock reaches $25.00 per share during the seven year option period.
• F3: Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
• F4: Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.
• F5: Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.
• F6: The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.